Cargando…
Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents
BACKGROUND: Our previous work has shown peroxiredoxin-1 (PRDX1), one of major antioxidant enzymes, to be a biomarker in human breast cancer. Hereby, we further investigate the role of PRDX1, compared to its close homolog PRDX2, in mammary malignant cells. METHODS: CRISPR/Cas9- or RNAi-based methods...
Autores principales: | Bajor, Malgorzata, Zych, Agata O., Graczyk-Jarzynka, Agnieszka, Muchowicz, Angelika, Firczuk, Malgorzata, Trzeciak, Lech, Gaj, Pawel, Domagala, Antoni, Siernicka, Marta, Zagozdzon, Agnieszka, Siedlecki, Pawel, Kniotek, Monika, O’Leary, Patrick C., Golab, Jakub, Zagozdzon, Radoslaw |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189216/ https://www.ncbi.nlm.nih.gov/pubmed/30287919 http://dx.doi.org/10.1038/s41416-018-0263-y |
Ejemplares similares
-
New insights into redox homeostasis as a therapeutic target in B-cell malignancies
por: Graczyk-Jarzynka, Agnieszka, et al.
Publicado: (2017) -
Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells
por: Bajor, Malgorzata, et al.
Publicado: (2020) -
Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma
por: Trzeciecka, Anna, et al.
Publicado: (2015) -
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
por: Marhelava, Katsiaryna, et al.
Publicado: (2019) -
Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy
por: Domagala, Antoni, et al.
Publicado: (2018)